For US Healthcare Professionals

Read Important Safety Information

XOLAIR (omalizumab) Allergic Asthma Support For You

From diagnosis to treatment, every patient's experience is unique. If you've been prescribed XOLAIR, the Support For You Program is designed with YOU in mind. Our free comprehensive program provides relevant and timely support and resources to ensure you have a positive patient experience. SIGN UP NOW

XOLAIR (omalizumab) Allergic Asthma virtual education session
CALL TODAY TO SCHEDULE: 1-866-878-0493
XOLAIR (omalizumab) Support For You Checklist
Register for XOLAIR (omalizumab) Allergic Asthma Support For You

Your privacy is a priority for us. Your information will only be used for communication purposes. You can opt out of receiving communication from Support For You at any time. Please complete the form below to join Support For You.

Before providing your information, let’s confirm that you are eligible to join today.

Are you 18 years or older?*
Have you or the child you care for been prescribed XOLAIR?*
What is “your”/“the child you care for” prescription type?*

Contact Information

Why are we asking this? The support materials you are signing up to receive include emails with useful information and tools to help you with your treatment experience.

Best phone to reach you:
OK to leave a voicemail?

*Indicates a required field.

I authorize Genentech USA, Inc. and Novartis Pharmaceuticals Corporation and their respective affiliates ("Sponsors") to enroll me to receive support materials about XOLAIR. I understand that my personally identifiable information is required for participation in the program. By enrolling to receive these support materials, I understand that my personal information will be used by Sponsors to provide me with information regarding the program, my disease, related conditions and/or treatment options. My personal information may also be used to improve the support program and to help the Sponsors manage their businesses. My personal information will not be sold. I understand and agree that my personally identifiable information will be shared with the Sponsors, their successors, their agents, and as otherwise required by law, and my healthcare provider. It will not be shared with anyone else unless required by law. I agree that I may be contacted in the future by mail, e-mail, and/or telephone concerning these support materials. I understand that I do not have to authorize enrollment in order to receive XOLAIR or to participate in the Access Solutions and Genentech® Patient Foundation program and that I may cancel this authorization at any time by calling 1-866-496-5247. By clicking the button below, I agree to the Terms and Conditions, confirm that I am 18 years of age or older, and may complete my sign-up.

By providing my phone number, I consent to enroll in disease-specific education, support programs, market research and communication that may be considered marketing. I understand my personally identifiable information may be needed for me to participate in these programs. I authorize Genentech to use auto-dialers, prerecorded messages and artificial voice messages to contact me. I understand that these calls may mention the name of Genentech products or services, details about my insurance coverage and my doctor’s name. I understand that I am not required to consent to being contacted by phone as a condition of any purchase of Genentech products or enrollment.

Support For You is for XOLAIR patients only. If you are considering XOLAIR treatment, visit the resource tab on XOLAIR.com to download a doctor discussion guide and the patient treatment guide.

We’re sorry. Patients under the age of 18 are not eligible to join Support For You.

Thank you

Your request has been submitted.

IMPORTANT SAFETY INFORMATION & INDICATION

What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not well controlled with asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if you have allergies to year-round allergens. It is not known if XOLAIR is safe and effective in people with asthma under 6 years of age.

XOLAIR is not used to treat other allergic conditions or sudden breathing problems.

What is the most important information I should know about XOLAIR? 

Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:

  • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
  • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”
  • flushing, itching, hives, or feeling warm
  • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction.

Do not receive and use XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR.

Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you:
  • have a latex allergy or any other allergies (such as food allergy or seasonal allergies). The needle cap on the XOLAIR prefilled syringe contains a type of natural rubber latex
  • have sudden breathing problems (bronchospasm)
  • have ever had a severe allergic reaction called anaphylaxis
  • have or have had a parasitic infection
  • have or have had cancer
  • are pregnant or plan to become pregnant. It is not known if XOLAIR may harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive and use XOLAIR.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I receive and use XOLAIR?
  • When starting treatment XOLAIR should be given by your healthcare provider in a healthcare setting.
  • If your healthcare provider decides that you or a caregiver may be able to give your own XOLAIR prefilled syringe injections, you should receive training on the right way to prepare and inject XOLAIR.
  • Do not try to inject your XOLAIR prefilled syringe until you have been shown the right way to give XOLAIR injections by a healthcare provider. Use XOLAIR exactly as prescribed by your healthcare provider. For children 12 years of age and older, XOLAIR prefilled syringe may be self-injected under adult supervision. For children 6 to 11 years of age, XOLAIR prefilled syringe should be injected by a caregiver.
  • See the detailed Instructions for Use that comes with XOLAIR for information on the right way to prepare and inject XOLAIR.
  • XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks.
  • In people with asthma, a blood test for a substance called IgE must be performed before starting XOLAIR to determine the appropriate dose and dosing frequency.
  • Do not decrease or stop taking any of your other asthma medicine unless your healthcare providers tell you to.
  • You may not see improvement in your symptoms right away after XOLAIR treatment. If your asthma symptoms do not improve or get worse, call your healthcare provider.
  • If you inject more XOLAIR than prescribed, call your healthcare provider right away.
What are the possible side effects of XOLAIR?
XOLAIR may cause serious side effects, including:
  • Cancer. Cases of cancer were observed in some people who received XOLAIR.
  • Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive XOLAIR. This usually, but not always, happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by XOLAIR. Tell your healthcare provider right away if you have rash; chest pain; shortness of breath; or a feeling of pins and needles or numbness of your arms or legs.
  • Fever, muscle aches, and rash. Some people get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider.
  • Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection.
  • Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether these are caused by XOLAIR
The most common side effects of XOLAIR:
  • In adults and children 12 years of age and older with asthma: joint pain especially in your arms and legs, dizziness, feeling tired, itching, skin rash, bone fractures, and pain or discomfort of your ears.
  • In children 6 to less than 12 years of age with asthma: swelling of the inside of your nose, throat, or sinuses, headache, fever, throat infection, ear infection, abdominal pain, stomach infection, and nose bleeds.

These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.

Please see full Prescribing Information, including Medication Guide for additional Important Safety Information and Instructions for Use.